improve study: mrd assessment as an endpoint to define treatment length and intensity in cll
Published 9 months ago • 120 plays • Length 2:22Download video MP4
Download video MP3
Similar videos
-
3:26
miracle study: using an mrd-guided strategy to direct treatment duration in previously untreated cll
-
1:11
integrating mrd data into treatment decisions in cll
-
1:40
mrd as a marker for depth of remission in cll
-
2:35
an update on mrd assessment and novel techniques used in the treatment of hematological malignancies
-
2:25
the clinical use of mrd in cll and challenges in this space
-
1:49
car-t cell approaches in cll: current progress & future directions
-
1:21
improving mrd assessment and response criteria in dlbcl: insights into phased-seq
-
1:40
the role of mrd in decision-making in cll
-
11:25
rcis q&a | study tips, rcis, arrt ci & more
-
5:25
should patients with aml who are mrd-positive proceed to allogeneic stem cell transplantation?
-
2:44
cll space: current treatment options and next steps
-
1:39
how can mrd guide treatment of aml?
-
0:45
key trials in cll and designing a concept for treatment
-
1:29
the importance of treatment sequencing in cll
-
0:48
pre-measure study: assessing the role of ngs mrd in patients with aml receiving sct
-
1:58
the future role of mrd measurement in cll
-
2:08
prognostic value of high-sensitivity mrd assessment in cll
-
1:44
how mrd assessment can inform treatment decisions in aml
-
2:07
significance of mrd in cll
-
4:21
mrd as a monitoring technique of allosct and car-t in aml/all
-
1:00
findings from the commands study and the approval of luspatercept for lower-risk mds
-
1:13
mrd: a valuable tool in cll